Company database

International CRO China platform. Official materials discuss China IIT versus IND pathways and local CRO support for IITs. IQVIA and KunTuo are presented as one group platform to avoid double counting.

PC

Parexel China

Compare

International full-service CRO with China delivery and published early-phase partner-site information. Confirm the actual team, indication and protocol rather than assuming global coverage establishes IIT fit.

IC

ICON China

Compare

International CRO disclosing China/APAC clinical operations and a Beijing central laboratory. Contract clinical operations and laboratory scope separately; current IIT support is not established by the reviewed sources.

Thermo Fisher’s clinical research business. Its China page describes local regulatory, linguistic and operational support for development programs.

International CRO with official China locations and a multinational oncology case study. A case example does not establish experience across every indication or IIT pathway.

SH

Syneos Health China

Compare

International clinical development platform with officially listed Beijing and Shanghai offices. Assess integrated global delivery separately from local IIT scope and confirm current resources.

International full-service CRO with official evidence of Shanghai and Beijing clinical teams. Confirm current China full-service scope and IIT availability directly.

Japan-origin CRO whose China page describes Beijing operations, site selection and CRC support. Group physician-initiated research capability does not automatically establish China IIT delivery.

Japan-origin EPS China CRO platform disclosing Phase I–IV, data, statistics, monitoring, regulatory and PV services. China affiliates are consolidated; confirm the actual contracting entity.

Japan-origin global CRO with China multilingual teams and clinical development disclosed on its APAC page. Confirm inbound China project scope and IIT services separately.

Website explicitly markets China IIT services to global developers. Evidence is primarily self-description; verify the legal entity, onshore team, site contracts, sponsor references and case records.

Markets China clinical and IIT services for global clients. Listed as a specialist candidate, not an independently validated full-service CRO; verify the China delivery entity, staffing and track record.

CRO/consultancy focused on Western life-science companies entering China clinical research, with disclosed university-hospital relationships. Confirm current staffing, agreement validity and operational subcontracting.

Primarily provides site management and CRC services for domestic and international sponsors/CROs. SMO ClinPlus is distinct from GCP ClinPlus; site support is not full-service CRO management.

Discloses SMO, evidence-based medicine and digital research support. Listed separately so site and technology services are not confused with full-service CRO delivery.

China-origin medical-device clinical/regulatory CRO with international device development disclosures. Device-specific scope should not be assumed to cover innovative-drug IITs.

Tigermed-affiliated medical-device/IVD clinical and regulatory platform. Listed as a specialist business, not an independent group; drug IITs require separate team matching.